BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Aikens GB, Osmundson JR, Rivey MP. New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop 2014; 5(3): 188-203 [PMID: 25035821 DOI: 10.5312/wjo.v5.i3.188]
URL: https://www.wjgnet.com/2218-5836/full/v5/i3/188.htm
Number Citing Articles
1
Ranjan Pathak, Smith Giri, Paras Karmacharya, Madan Raj Aryal, Dilli Ram Poudel, Sushil Ghimire, Asad Jehangir, Bilal Shaikh, Andrew Rettew, Anthony A. Donato. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patientsBlood Coagulation & Fibrinolysis 2015; 26(8): 934 doi: 10.1097/MBC.0000000000000369
2
Shant Shirvanian, Victor F. Tapson. Venous thromboembolism: identifying patients at risk and establishing prophylaxisCurrent Medical Research and Opinion 2015; 31(12): 2297 doi: 10.1185/03007995.2015.1098599
3
Adriane Mayer, Philipp Schuster, Bernd Fink. A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgeryArchives of Orthopaedic and Trauma Surgery 2017; 137(6): 797 doi: 10.1007/s00402-017-2697-8
4
Dimitrios V. Papadopoulos, Ioannis Kostas-Agnantis, Ioannis Gkiatas, Andreas G. Tsantes, Panagiota Ziara, Anastasios V. Korompilias. The role of new oral anticoagulants in orthopaedics: an update of recent evidenceEuropean Journal of Orthopaedic Surgery & Traumatology 2017; 27(5): 573 doi: 10.1007/s00590-017-1940-x
5
Yeo Jin Choi, Yong Won Choi, Jung-woo Chae, Hwi-yeol Yun, Sooyoung Shin. Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana IndexRisk Management and Healthcare Policy 2021; : 1855 doi: 10.2147/RMHP.S306760